EUROPEAN MEDICAL SOLUTIONS S (ALEMS.BR) Stock Fundamental Analysis
Europe - Euronext Brussels - EBR:ALEMS - BE0974497290 - Common Stock
5.12 EUR
+0.5 (+10.81%)
Overall ALEMS gets a fundamental rating of 2 out of 10. We evaluated ALEMS against 82 industry peers in the Biotechnology industry. ALEMS has a medium profitability rating, but doesn't score so well on its financial health evaluation. ALEMS does not seem to be growing, but still is valued expensively.
1. Profitability
1.1 Basic Checks
ALEMS had positive earnings in the past year.
In the past year ALEMS had a positive cash flow from operations.
ALEMS had negative earnings in 4 of the past 5 years.
The reported operating cash flow has been mixed in the past 5 years: ALEMS reported negative operating cash flow in multiple years.
1.2 Ratios
ALEMS's Return On Assets of 2.25% is fine compared to the rest of the industry. ALEMS outperforms 74.39% of its industry peers.
With a decent Return On Equity value of 10.64%, ALEMS is doing good in the industry, outperforming 79.27% of the companies in the same industry.
ALEMS has a better Return On Invested Capital (4.80%) than 73.17% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 2.25% | ||
| ROE | 10.64% | ||
| ROIC | 4.8% |
ROA(3y)-7.51%
ROA(5y)-9.94%
ROE(3y)-29.52%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
ALEMS has a Profit Margin of 2.50%. This is in the better half of the industry: ALEMS outperforms 73.17% of its industry peers.
ALEMS has a Operating Margin of 4.13%. This is in the better half of the industry: ALEMS outperforms 70.73% of its industry peers.
ALEMS's Operating Margin has improved in the last couple of years.
ALEMS's Gross Margin of 21.27% is in line compared to the rest of the industry. ALEMS outperforms 40.24% of its industry peers.
In the last couple of years the Gross Margin of ALEMS has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 4.13% | ||
| PM (TTM) | 2.5% | ||
| GM | 21.27% |
OM growth 3Y225.98%
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.83%
GM growth 5YN/A
2. Health
2.1 Basic Checks
ALEMS has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
The number of shares outstanding for ALEMS has been reduced compared to 1 year ago.
ALEMS has more shares outstanding than it did 5 years ago.
Compared to 1 year ago, ALEMS has a worse debt to assets ratio.
2.2 Solvency
ALEMS has an Altman-Z score of -0.94. This is a bad value and indicates that ALEMS is not financially healthy and even has some risk of bankruptcy.
ALEMS's Altman-Z score of -0.94 is in line compared to the rest of the industry. ALEMS outperforms 40.24% of its industry peers.
A Debt/Equity ratio of 1.24 is on the high side and indicates that ALEMS has dependencies on debt financing.
The Debt to Equity ratio of ALEMS (1.24) is worse than 62.20% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.24 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -0.94 |
ROIC/WACC0.81
WACC5.9%
2.3 Liquidity
A Current Ratio of 1.41 indicates that ALEMS should not have too much problems paying its short term obligations.
With a Current ratio value of 1.41, ALEMS is not doing good in the industry: 64.63% of the companies in the same industry are doing better.
ALEMS has a Quick Ratio of 1.41. This is a bad value and indicates that ALEMS is not financially healthy enough and could expect problems in meeting its short term obligations.
Looking at the Quick ratio, with a value of 0.89, ALEMS is doing worse than 73.17% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.41 | ||
| Quick Ratio | 0.89 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 4809.09% over the past year.
The Revenue has grown by 12.39% in the past year. This is quite good.
ALEMS shows a small growth in Revenue. Measured over the last years, the Revenue has been growing by 7.56% yearly.
EPS 1Y (TTM)4809.09%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%169.01%
Revenue 1Y (TTM)12.39%
Revenue growth 3Y7.56%
Revenue growth 5YN/A
Sales Q2Q%7.52%
3.2 Future
No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
4. Valuation
4.1 Price/Earnings Ratio
ALEMS is valuated rather expensively with a Price/Earnings ratio of 18.96.
Based on the Price/Earnings ratio, ALEMS is valued cheaply inside the industry as 81.71% of the companies are valued more expensively.
ALEMS is valuated rather cheaply when we compare the Price/Earnings ratio to 26.57, which is the current average of the S&P500 Index.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 18.96 | ||
| Fwd PE | N/A |
4.2 Price Multiples
ALEMS's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. ALEMS is cheaper than 90.24% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | 7.62 |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A
5. Dividend
5.1 Amount
No dividends for ALEMS!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
EBR:ALEMS (12/24/2025, 7:00:00 PM)
5.12
+0.5 (+10.81%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners0.02%
Inst Owner ChangeN/A
Ins Owners1.2%
Ins Owner ChangeN/A
Market Cap21.66M
Revenue(TTM)46.78M
Net Income(TTM)1.17M
Analysts34.29
Price TargetN/A
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 18.96 | ||
| Fwd PE | N/A | ||
| P/S | 0.46 | ||
| P/FCF | N/A | ||
| P/OCF | 9.71 | ||
| P/B | 1.97 | ||
| P/tB | 21.66 | ||
| EV/EBITDA | 7.62 |
EPS(TTM)0.27
EY5.27%
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)-0.2
FCFYN/A
OCF(TTM)0.53
OCFY10.3%
SpS11.06
BVpS2.6
TBVpS0.24
PEG (NY)N/A
PEG (5Y)N/A
Graham Number3.97
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 2.25% | ||
| ROE | 10.64% | ||
| ROCE | 7.72% | ||
| ROIC | 4.8% | ||
| ROICexc | 5.49% | ||
| ROICexgc | 9.08% | ||
| OM | 4.13% | ||
| PM (TTM) | 2.5% | ||
| GM | 21.27% | ||
| FCFM | N/A |
ROA(3y)-7.51%
ROA(5y)-9.94%
ROE(3y)-29.52%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3Y196.14%
ROICexgc growth 5YN/A
ROICexc growth 3Y198.9%
ROICexc growth 5YN/A
OM growth 3Y225.98%
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.83%
GM growth 5YN/A
F-Score6
Asset Turnover0.9
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.24 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | 3.27 | ||
| Cap/Depr | 136.44% | ||
| Cap/Sales | 6.56% | ||
| Interest Coverage | 2.44 | ||
| Cash Conversion | 53.35% | ||
| Profit Quality | N/A | ||
| Current Ratio | 1.41 | ||
| Quick Ratio | 0.89 | ||
| Altman-Z | -0.94 |
F-Score6
WACC5.9%
ROIC/WACC0.81
Cap/Depr(3y)97.31%
Cap/Depr(5y)N/A
Cap/Sales(3y)6.88%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)4809.09%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%169.01%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)12.39%
Revenue growth 3Y7.56%
Revenue growth 5YN/A
Sales Q2Q%7.52%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y438%
EBIT growth 3Y250.62%
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y70.93%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y232.84%
OCF growth 3Y94.49%
OCF growth 5YN/A
EUROPEAN MEDICAL SOLUTIONS S / ALEMS.BR FAQ
What is the fundamental rating for ALEMS stock?
ChartMill assigns a fundamental rating of 2 / 10 to ALEMS.BR.
Can you provide the valuation status for EUROPEAN MEDICAL SOLUTIONS S?
ChartMill assigns a valuation rating of 2 / 10 to EUROPEAN MEDICAL SOLUTIONS S (ALEMS.BR). This can be considered as Overvalued.
Can you provide the profitability details for EUROPEAN MEDICAL SOLUTIONS S?
EUROPEAN MEDICAL SOLUTIONS S (ALEMS.BR) has a profitability rating of 4 / 10.
What is the valuation of EUROPEAN MEDICAL SOLUTIONS S based on its PE and PB ratios?
The Price/Earnings (PE) ratio for EUROPEAN MEDICAL SOLUTIONS S (ALEMS.BR) is 18.96 and the Price/Book (PB) ratio is 1.97.
Can you provide the financial health for ALEMS stock?
The financial health rating of EUROPEAN MEDICAL SOLUTIONS S (ALEMS.BR) is 1 / 10.